$80MSeries B, 2 September 2025
Funds clinical launch of its lead menin inhibitor in AML in early 2026.
- Amount
- $80M
- Stage
- Series B
- Announced
- 2 September 2025
- Lead
- New Enterprise Associates
- Other investors
- SR One, NVIDIA, OrbiMed, F-Prime, Khosla Ventures
- Use of funds
- Funds clinical launch of its lead menin inhibitor in AML in early 2026.
- Checked
- Amount and date checked against the press source
- Source
- CHARM Therapeutics raises $80M Series B (tech.eu lists Sep 2) pulse2.com